Evidence map›Paper›PMID 32051502›Full record

ArticleScientific reports2020

Cerebrospinal fluid proteomics implicates the granin family in Parkinson's disease.

Melissa S Rotunno, Monica Lane, Wenfei Zhang, Pavlina Wolf, Petra Oliva, Catherine Viel, Anne-Marie Wills, Roy N Alcalay, Clemens R Scherzer, Lamya S Shihabuddin and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 3 pooled it
8.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Proteomic Exploration of L1CAMInternational journal of molecular sciences · 2025
    Article
  8. Association between ultra-short heart rate variability and risk of Parkinson's disease: a prospective cohort study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Melissa S RotunnoRare and Neurologic Diseases Therapeutic Area, Sanofi, Inc., Framingham, MA, 01701, USA.
Monica LaneBiomarkers and Bioanalytics, Translational Sciences, Sanofi, Inc., Framingham, MA, 01701, USA.
Wenfei ZhangTranslational Medicine, Sanofi, Inc., Framingham, MA, 01701, USA.
Pavlina WolfBiomarkers and Bioanalytics, Translational Sciences, Sanofi, Inc., Framingham, MA, 01701, USA.
Petra OlivaBiomarkers and Bioanalytics, Translational Sciences, Sanofi, Inc., Framingham, MA, 01701, USA.
Catherine VielRare and Neurologic Diseases Therapeutic Area, Sanofi, Inc., Framingham, MA, 01701, USA.
Anne-Marie WillsDepartment of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA.
Roy N AlcalayDepartment of Neurology, Columbia University, New York, NY, 10032-3784, USA.ORCID http://orcid.org/0000-0002-5717-4875
Clemens R ScherzerPrecision Neurology Program, Harvard Medical School, Brigham & Women's Hospital, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0002-0567-9193
Lamya S ShihabuddinRare and Neurologic Diseases Therapeutic Area, Sanofi, Inc., Framingham, MA, 01701, USA.
Kate ZhangBiomarkers and Bioanalytics, Translational Sciences, Sanofi, Inc., Framingham, MA, 01701, USA.
S Pablo SardiRare and Neurologic Diseases Therapeutic Area, Sanofi, Inc., Framingham, MA, 01701, USA. pablo.sardi@sanofi.com.ORCID http://orcid.org/0000-0001-9805-3677
Sanofi (United States) · USEditas Medicine (United States) · USBOKU University · ATBrigham and Women's Hospital · USColumbia University · USMassachusetts General Hospital · USSanofi (France) · FR

Funding

THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
Integrative Multi-Omic Discovery of Proximal Mechanisms Driving Age-Dependent NeurodegenerationRF1AG057331 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI FEANY, MEL B, FRAENKEL, ERNEST · 2017 to 2017
$4.8M
GBA pathway markers for Lewy body dementiasU01NS100603 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2016 to 2020
$2.9M
Biomarkers for early intervention in Parkinson diseaseU01NS082157 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2012 to 2016
$2.5M
Parkinson Disease: Predicting the FutureU01NS095736 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2016 to 2018
$2.1M
AGE ASSOCIATED CHANGES IN B LYMPHOCYTE FUNCTIONR01AG005731 · NIA · UNIVERSITY OF KENTUCKY · PI BONDADA, SUBBARAO · 1986 to 2005
$1.7M
NIA NIH HHS P50 AG005134NIA NIH HHS R01 AG005731NIA NIH HHS RF1 AG057331NINDS NIH HHS U01 NS082157NINDS NIH HHS U01 NS095736NINDS NIH HHS U01 NS100603
6 · The paper itself

Abstract

Parkinson's disease, the most common age-related movement disorder, is a progressive neurodegenerative disease with unclear etiology. Better understanding of the underlying disease mechanism(s) is an urgent need for the development of disease-modifying therapeutics. Limited studies have been performed in large patient cohorts to identify protein alterations in cerebrospinal fluid (CSF), a proximal site to pathology. We set out to identify disease-relevant protein changes in CSF to gain insights into the etiology of Parkinson's disease and potentially assist in disease biomarker identification. In this study, we used liquid chromatography-tandem mass spectrometry in data-independent acquisition (DIA) mode to identify Parkinson's-relevant biomarkers in cerebrospinal fluid. We quantified 341 protein groups in two independent cohorts (n = 196) and a longitudinal cohort (n = 105 samples, representing 40 patients) consisting of Parkinson's disease and healthy control samples from three different sources. A first cohort of 53 Parkinson's disease and 72 control samples was analyzed, identifying 53 proteins with significant changes (p < 0.05) in Parkinson's disease relative to healthy control. We established a biomarker signature and multiple protein ratios that differentiate Parkinson's disease from healthy controls and validated these results in an independent cohort. The second cohort included 28 Parkinson's disease and 43 control samples. Independent analysis of these samples identified 41 proteins with significant changes. Evaluation of the overlapping changes between the two cohorts identified 13 proteins with consistent and significant changes (p < 0.05). Importantly, we found the extended granin family proteins as reduced in disease, suggesting a potential common mechanism for the biological reduction in monoamine neurotransmission in Parkinson's patients. Our study identifies several novel protein changes in Parkinson's disease cerebrospinal fluid that may be exploited for understanding etiology of disease and for biomarker development.

Indexed as

AgedBiomarkersChromograninsFemaleHumansMaleMiddle AgedParkinson DiseaseProteomicsTandem Mass SpectrometryBiomarkersChromogranins

Identifiers

PMID32051502
PMCPMC7015906
OpenAlexW3005908769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.